Published in Cardiovasc Diabetol on December 05, 2011
Aspirin Non-responsiveness and Clopidogrel Endpoint Trial. (ASCET) | NCT00222261
Several genetic polymorphisms interact with overweight/obesity to influence serum lipid levels. Cardiovasc Diabetol (2012) 1.12
The co-existence of the IL-18+183 A/G and MMP-9 -1562 C/T polymorphisms is associated with clinical events in coronary artery disease patients. PLoS One (2013) 0.83
Genetic polymorphisms of cytokine genes in type 2 diabetes mellitus. World J Diabetes (2014) 0.81
Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men. Prostate Cancer Prostatic Dis (2013) 0.79
The CTGF gene -945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes. Cardiovasc Diabetol (2012) 0.78
Increased IL18 mRNA levels in peripheral artery disease and its association with triglyceride and LDL cholesterol levels: a pilot study. Heart Vessels (2015) 0.76
Gly1057Asp polymorphism of insulin receptor substrate-2 is associated with coronary artery disease in the Taiwanese population. J Biomed Sci (2012) 0.75
Association between interleukin-6/6R gene polymorphisms and coronary artery disease in Russian population: influence of interleukin-6/6R gene polymorphisms on inflammatory markers. J Inflamm Res (2017) 0.75
Increased adipose tissue expression of IL-18R and its ligand IL-18 associates with inflammation and insulin resistance in obesity. Immun Inflamm Dis (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature (1995) 10.89
Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest (1994) 7.25
Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science (1997) 5.16
Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity (1999) 3.43
Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation (2005) 3.02
Interleukin-18. J Leukoc Biol (2003) 2.75
Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc Natl Acad Sci U S A (1999) 2.57
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol (2005) 2.31
Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation (2003) 2.26
Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol (2005) 2.17
Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation (2001) 2.13
Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol (2001) 2.11
Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med (2002) 1.91
Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. Diabetes Care (2003) 1.81
The structure and binding mode of interleukin-18. Nat Struct Biol (2003) 1.42
A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine (2001) 1.41
The role of interleukin-18 in the metabolic syndrome. Cardiovasc Diabetol (2010) 1.23
Beta-adrenergic stimulation induces interleukin-18 expression via beta2-AR, PI3K, Akt, IKK, and NF-kappaB. Biochem Biophys Res Commun (2004) 1.14
Interleukin-18 genetics and inflammatory disease susceptibility. Genes Immun (2007) 1.11
Gamma interferon: a central mediator in atherosclerosis. Inflamm Res (2005) 1.09
IL-18 gene polymorphisms affect IL-18 production capability by monocytes. Biochem Biophys Res Commun (2006) 1.08
Interferon-gamma mediates gene expression of IL-18 binding protein in nonleukocytic cells. Biochem Biophys Res Commun (2000) 1.06
Reduced transcriptional activity in individuals with IL-18 gene variants detected from functional but not association study. Biochem Biophys Res Commun (2005) 1.04
Circulating IL-18 and the risk of type 2 diabetes in women. Diabetologia (2009) 1.04
Cytokine milieu tends toward inflammation in type 2 diabetes. Diabetes Care (2003) 1.00
Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia. Diabetes Care (2008) 0.98
Interleukin 18 and coronary heart disease: prospective study and systematic review. Atherosclerosis (2011) 0.98
The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat Clin Pract Cardiovasc Med (2009) 0.97
Differential haplotypic expression of the interleukin-18 gene. Eur J Hum Genet (2007) 0.94
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J (2004) 0.92
Free Interleukin (IL)-18 levels, and the impact of IL18 and IL18BP genetic variation, in CHD patients and healthy men. Arterioscler Thromb Vasc Biol (2007) 0.89
Impact of inflammatory markers on cardiovascular mortality in patients with metabolic syndrome. Eur J Cardiovasc Prev Rehabil (2008) 0.88
IL-18 gene polymorphism and metabolic syndrome. Nutr Metab Cardiovasc Dis (2009) 0.87
Interleukin-18 promoter polymorphism associates with the occurrence of sudden cardiac death among Caucasian males: the Helsinki Sudden Death Study. Atherosclerosis (2007) 0.87
Gender difference in granulocyte dynamics and apoptosis and the role of IL-18 during endotoxin-induced systemic inflammation. Shock (2009) 0.86
IL-18 initiates release of matrix metalloproteinase-9 from peripheral blood mononuclear cells without affecting tissue inhibitor of matrix metalloproteinases-1: suppression by TNF alpha blockage and modulation by IL-10. Naunyn Schmiedebergs Arch Pharmacol (2002) 0.86
Adipose tissue expression of interleukin-18 mRNA is elevated in subjects with metabolic syndrome and independently associated with fasting glucose. Wien Klin Wochenschr (2011) 0.83
Arterial stiffness is independently associated with interleukin-18 and components of the metabolic syndrome. Atherosclerosis (2009) 0.81
Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med (2006) 7.28
Warfarin, aspirin, or both after myocardial infarction. N Engl J Med (2002) 6.85
The anesthesia in abdominal aortic surgery (ABSENT) study: a prospective, randomized, controlled trial comparing troponin T release with fentanyl-sevoflurane and propofol-remifentanil anesthesia in major vascular surgery. Anesthesiology (2013) 3.38
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29
Low heart rates predict incident atrial fibrillation in healthy middle-aged men. Circ Arrhythm Electrophysiol (2013) 2.12
Marine n-3 polyunsaturated fatty acids and coronary heart disease. Part I. Background, epidemiology, animal data, effects on risk factors and safety. Thromb Res (2005) 1.62
Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol (2012) 1.60
Increased circulating mitochondrial DNA after myocardial infarction. Int J Cardiol (2012) 1.58
Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study. Hypertension (2012) 1.57
Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol (2007) 1.48
The association between metabolic syndrome and infarct size in patients with acute myocardial infarction. Scand J Clin Lab Invest (2010) 1.45
Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol (2006) 1.45
Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J (2013) 1.44
Decreased levels of asymmetric dimethylarginine during acute hyperinsulinemia. Metabolism (2007) 1.42
Less benefit from warfarin in diabetics after myocardial infarction? Cardiology (2008) 1.40
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2013) 1.36
Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J (2011) 1.34
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy. Am J Cardiol (2010) 1.30
The role of interleukin-18 in the metabolic syndrome. Cardiovasc Diabetol (2010) 1.23
Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J (2011) 1.23
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost (2009) 1.21
Autologous stem cell transplantation in acute myocardial infarction: The ASTAMI randomized controlled trial. Intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects. Scand Cardiovasc J (2005) 1.21
Patients' experiences with symptoms and needs in the early rehabilitation phase after coronary artery bypass grafting. Eur J Cardiovasc Nurs (2012) 1.17
High prevalence of atrial fibrillation in long-term endurance cross-country skiers: echocardiographic findings and possible predictors--a 28-30 years follow-up study. Eur J Cardiovasc Prev Rehabil (2010) 1.15
Abnormal glucose regulation in patients with acute ST- elevation myocardial infarction-a cohort study on 224 patients. Cardiovasc Diabetol (2009) 1.15
Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. Diabetes (2002) 1.14
Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism (2004) 1.10
Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res (2002) 1.06
Dairy products and metabolic effects in overweight men and women: results from a 6-mo intervention study. Am J Clin Nutr (2009) 1.02
Influence of long-term intervention with dietary counseling, long-chain n-3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long-standing hyperlipidemia. Am J Clin Nutr (2005) 1.00
General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2013) 0.99
Anterior myocardial infarction with acute percutaneous coronary intervention and intracoronary injection of autologous mononuclear bone marrow cells: safety, clinical outcome, and serial changes in left ventricular function during 12-months' follow-up. J Am Coll Cardiol (2008) 0.98
Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia. Diabetes Care (2008) 0.98
Age and stress related phenotypical changes in bone marrow CD34+ cells. Scand J Clin Lab Invest (2009) 0.95
The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care (2012) 0.95
Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis (2003) 0.94
Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. Heart (2011) 0.94
Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. Eur J Cardiovasc Prev Rehabil (2006) 0.94
No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand Cardiovasc J (2002) 0.93
Renal tubulointerstitial expansion is associated with endothelial dysfunction and inflammation in type 1 diabetes. Scand J Clin Lab Invest (2009) 0.93
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J (2004) 0.92
Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease. Clin Chim Acta (2011) 0.92
Blood cell gene expression associated with cellular stress defense is modulated by antioxidant-rich food in a randomised controlled clinical trial of male smokers. BMC Med (2010) 0.91
Inflammatory responses after percutaneous coronary intervention in patients with acute myocardial infarction or stable angina pectoris. Scand J Clin Lab Invest (2008) 0.90
Components of the interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness. Metabolism (2013) 0.90
Importance of physical fitness on predictive effect of body mass index and weight gain on incident atrial fibrillation in healthy middle-age men. Am J Cardiol (2012) 0.90
Regional myocardial function after intracoronary bone marrow cell injection in reperfused anterior wall infarction - a cardiovascular magnetic resonance tagging study. J Cardiovasc Magn Reson (2011) 0.89
Frailty measures, inflammatory biomarkers and post-operative complications in older surgical patients. Age Ageing (2010) 0.89
High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J Am Heart Assoc (2012) 0.89
A comparison of the effects of cheese and butter on serum lipids, haemostatic variables and homocysteine. Br J Nutr (2004) 0.88
Effect of lifestyle changes on atherogenic lipids and endothelial cell adhesion molecules in young adults with familial premature coronary heart disease. Am J Cardiol (2005) 0.88
Supplementation with fish oil affects the association between very long-chain n-3 polyunsaturated fatty acids in serum non-esterified fatty acids and soluble vascular cell adhesion molecule-1. Clin Sci (Lond) (2003) 0.88
The effect of exercise on serum levels of interleukin-18 and components of the metabolic syndrome. Metab Syndr Relat Disord (2009) 0.87
Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis (2002) 0.86
Activin A levels are associated with abnormal glucose regulation in patients with myocardial infarction: potential counteracting effects of activin A on inflammation. Diabetes (2011) 0.86
Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. J Biomed Biotechnol (2010) 0.86
Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. Eur J Heart Fail (2013) 0.86
Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Am J Cardiol (2003) 0.86
Increased levels of CRP and MCP-1 are associated with previously unknown abnormal glucose regulation in patients with acute STEMI: a cohort study. Cardiovasc Diabetol (2010) 0.85
Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men. Metabolism (2009) 0.85
Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes. Thromb J (2010) 0.85
A long-term follow-up study of chest pain patients: effect of panic disorder on mortality, morbidity, and quality of life. Cardiology (2007) 0.84
The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina. Thromb Res (2009) 0.84
Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res (2002) 0.84
Inflammatory responses after intracoronary injection of autologous mononuclear bone marrow cells in patients with acute myocardial infarction. Am Heart J (2008) 0.84
Vitamin C consumption is associated with less progression in carotid intima media thickness in elderly men: A 3-year intervention study. Nutr Metab Cardiovasc Dis (2008) 0.84